A detailed history of ETF Managers Group, LLC transactions in Cel Sci Corp stock. As of the latest transaction made, ETF Managers Group, LLC holds 14,522 shares of CVM stock, worth $10,601. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,522
Previous 10,812 34.31%
Holding current value
$10,601
Previous $25,000 32.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

BUY
$2.17 - $3.13 $8,050 - $11,612
3,710 Added 34.31%
14,522 $33,000
Q4 2022

Mar 23, 2023

SELL
$1.99 - $3.52 $3,950 - $6,987
-1,985 Reduced 15.51%
10,812 $25,000
Q3 2022

Nov 14, 2022

SELL
$3.09 - $5.23 $2,756 - $4,665
-892 Reduced 6.52%
12,797 $40,000
Q2 2022

Aug 15, 2022

BUY
$2.58 - $4.99 $1,449 - $2,804
562 Added 4.28%
13,689 $61,000
Q1 2022

May 13, 2022

BUY
$3.93 - $7.7 $463 - $908
118 Added 0.91%
13,127 $52,000
Q4 2021

Feb 14, 2022

SELL
$7.1 - $12.82 $10,429 - $18,832
-1,469 Reduced 10.15%
13,009 $98,000
Q3 2021

Nov 15, 2021

BUY
$7.64 - $12.49 $18,420 - $30,113
2,411 Added 19.98%
14,478 $160,000
Q2 2021

Aug 16, 2021

SELL
$8.68 - $27.49 $3,046 - $9,648
-351 Reduced 2.83%
12,067 $155,000
Q1 2021

May 17, 2021

SELL
$12.0 - $27.64 $77,076 - $177,531
-6,423 Reduced 34.09%
12,418 $193,000
Q4 2020

Feb 16, 2021

SELL
$11.05 - $16.62 $30,928 - $46,519
-2,799 Reduced 12.93%
18,841 $228,000
Q3 2020

Nov 16, 2020

BUY
$11.69 - $14.54 $124,790 - $155,214
10,675 Added 97.36%
21,640 $267,000
Q2 2020

Aug 14, 2020

BUY
$9.75 - $17.6 $106,908 - $192,984
10,965 New
10,965 $172,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $31.7M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.